110 related articles for article (PubMed ID: 29362275)
1. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
2. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
3. Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European Union.
Fukuda K; Narukawa M
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1331-1340. PubMed ID: 37395168
[TBL] [Abstract][Full Text] [Related]
4. Medication errors: pharmacovigilance centres in detection and prevention.
Bencheikh RS; Benabdallah G
Br J Clin Pharmacol; 2009 Jun; 67(6):687-90. PubMed ID: 19594539
[TBL] [Abstract][Full Text] [Related]
5. Withdrawn 2.0-update on withdrawn drugs with pharmacovigilance data.
Gallo K; Goede A; Eckert OA; Gohlke BO; Preissner R
Nucleic Acids Res; 2024 Jan; 52(D1):D1503-D1507. PubMed ID: 37971295
[TBL] [Abstract][Full Text] [Related]
6. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.
Lexchin J
Open Med; 2014; 8(1):e14-9. PubMed ID: 25009681
[TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance and Appropriate Drug Use.
Gozzo L
Healthcare (Basel); 2024 Mar; 12(6):. PubMed ID: 38540633
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the International Ambulatory Drug Safety Symposium: Munich, Germany, June 2023.
Alexander GC; Budnitz D; Hughes C; Maas R; Mair A; McDonald EG; Meid AD; Payne R; Seidling HM; Shakir S; Suissa S; Tannenbaum C; Schneeweiss S; Dreischulte T
Drug Saf; 2024 Jan; 47(1):103-111. PubMed ID: 37917316
[No Abstract] [Full Text] [Related]
9. Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical Utility.
Kara V; Powell G; Mahaux O; Jayachandra A; Nyako N; Golds C; Bate A
Drug Saf; 2023 Sep; 46(9):847-855. PubMed ID: 37535258
[TBL] [Abstract][Full Text] [Related]
10. Identification of Drug-Cancer Associations: A Nationwide Screening Study.
Kristensen KB; Friis S; Lund LC; Hallas J; Cardwell CR; Andreassen BK; Habel LA; Pottegård A
Cancer Res Commun; 2022 Jun; 2(6):552-560. PubMed ID: 36923552
[TBL] [Abstract][Full Text] [Related]
11. Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis.
Li Y; Jiang Y; Wang H; Zhang L; Yang Y
Drug Saf; 2022 Jul; 45(7):737-745. PubMed ID: 35821561
[TBL] [Abstract][Full Text] [Related]
12. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
Caster O; Aoki Y; Gattepaille LM; Grundmark B
Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
[TBL] [Abstract][Full Text] [Related]
13. Undergraduate and postgraduate pharmacovigilance education: A proposal for appropriate curriculum content.
Herrera Comoglio R
Br J Clin Pharmacol; 2020 Apr; 86(4):779-790. PubMed ID: 31770452
[TBL] [Abstract][Full Text] [Related]
14. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
[TBL] [Abstract][Full Text] [Related]
15. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
16. How Clinical Practice Research Datalink data are used to support pharmacovigilance.
Ghosh RE; Crellin E; Beatty S; Donegan K; Myles P; Williams R
Ther Adv Drug Saf; 2019; 10():2042098619854010. PubMed ID: 31210923
[TBL] [Abstract][Full Text] [Related]
17. Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance.
Arlett P
Drug Saf; 2019 May; 42(5):581-582. PubMed ID: 30637598
[No Abstract] [Full Text] [Related]
18. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
Lexchin J
CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
[TBL] [Abstract][Full Text] [Related]
19. First Conference on Big Data for Pharmacovigilance.
Min J; Osborne V; Lynn E; Shakir SAW
Drug Saf; 2018 Dec; 41(12):1281-1284. PubMed ID: 30232742
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
